<DOC>
	<DOCNO>NCT00992134</DOCNO>
	<brief_summary>The objective study demonstrate safety , tolerability , activity Rituximab-Bendamustine-Cytarabine ( R-BAC ) regimen patient mantle cell lymphoma ( MCL ) age 65 year , well young patient eligible intensive regimen including/not include autologous transplantation .</brief_summary>
	<brief_title>Immunochemotherapy With Rituximab-Bendamustine-Cytarabine ( R-BAC ) Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>Since Bendamustine recently show promising safety efficacy combination monoclonal antibody treatment patient MCL , goal study investigate possible therapeutic benefit combine Ara-C Bendamustine Rituximab ( R-BAC ) . All three agent exhibit individual unique mechanism action MCL , synergistic additive effect might expect agent use combination , suggest pre-clinical study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Previously untreated patient MCL age 65 year , &lt; 65 year eligible intensive treatment including/not include autologous transplantation . MCL patient age relapse/progress resistant one line chemotherapy . CD20+ . Karnofsky score least 70 % Adequate renal function ( Creatinine clearance &gt; 40 mL/min ) , preserve diuresis . Adequate liver function : alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) &lt; 2.5 x upper limit normal ( ULN ) value , total bilirubin &lt; 2 mg/dL , unless directly attributable patient 's tumor . Negative serum pregnancy test 1 week prior treatment premenopausal woman woman &lt; 2 year onset menopause . Hepatitis B core antibody ( HBcAb ) positive patient may enrol correct antiviral prophylaxis administer least 2 week initiate protocol treatment . Written informed consent . Prior treatment Bendamustine . Refractoriness Rituximab , define progressive disease previous cycle include drug , relapse within 6 month previous cycle include Rituximab . Previous Rituximab infusionrelated severe reaction . Human immunodeficiency virus ( HIV ) positive . Medical condition organ injury could interfere administration therapy . Active bacterial , viral , fungal infection require systemic therapy . Seizure disorder require anticonvulsant therapy . Severe chronic obstructive pulmonary disease hypoxaemia . History severe cardiac disease : New York Heart Association ( NYHA ) functional class IIIIV , myocardial infarction within 6 month , ventricular tachyarrhythmias , dilatative cardiomyopathy , unstable angina . Uncontrolled diabetes mellitus . Active secondary malignancy . Known hypersensitivity anaphylactic reaction murine antibody protein ( patient treat Rituximab ) , Bendamustine mannitol . Fertile men woman childbearing potential unless surgically sterile use adequate measure contraception . Major surgery within 4 week study Day 1 . HBsAg+ HCV+ patient Any coexist medical psychological condition would preclude participation study compromise patient 's ability give inform consent , may affect interpretation result , render patient high risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Lymphoma , Mantle-Cell</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Treatment</keyword>
	<keyword>Combination chemotherapy</keyword>
</DOC>